Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Berlex Launches Yasmin DTC Campaign; TV Spots Will Follow Print Ads

This article was originally published in The Pink Sheet Daily

Executive Summary

Yasmin print campaign revises previous ads called into question by FDA in a July 2003 "untitled" letter. Global sales of the oral contraceptive should approach $500 mil. in 2004.

You may also be interested in...



Barr To Resume Revised Seasonale DTC Ads By End Of January

Changes are being made to the voice-over in the television commercial for the extended-regimen oral contraceptive following a December FDA ad division letter. Barr will continue Seasonale DTC ads until the launch of Seasonique.

Natrecor Use Should Be Limited, Independent Panel Convened By J&J Says

The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel